Featured stories
- 16-12-2020 LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development
- 28-10-2020 LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
- 23-09-2020 LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
- 31-08-2020 LEO Pharma sells portfolio of four products to Cheplapharm
- 20-08-2020 LEO Pharma unveils ambitious 2030 strategy positioning itself for long-term growth driven by innovation
- 19-08-2020 LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications
- 30-06-2020 LEO Pharma strengthens global leadership team
- 13-03-2020 Updates regarding COVID-19
- 21-11-2019 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
- 19-11-2019 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
- 14-11-2019 Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
- 07-11-2019 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
- 30-10-2019 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
- 24-10-2019 World Psoriasis Day 2019: LEO Pharma launches new campaign to reduce the stigma surrounding psoriasis
- 01-07-2019 LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- 03-06-2019 LEO Pharma appoints Catherine Mazzacco as new CEO
- 10-05-2019 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
- 11-04-2019 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
- 09-04-2019 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
- 19-03-2019 LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
MEDIA ENQUIRIES
